» Articles » PMID: 39004686

Alendronate Treatment Rescues the Effects of Compressive Loading of TMJ in Osteogenesis Imperfecta Mice

Overview
Journal Prog Orthod
Publisher Springer
Specialty Dentistry
Date 2024 Jul 14
PMID 39004686
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue caused by mutations associated with type I collagen, which results in defective extracellular matrix in temporomandibular joint (TMJ) cartilage and subchondral bone. TMJ is a fibrocartilaginous joint expressing type I collagen both in the cartilage and the subchondral bone. In the present study the effects of alendronate and altered loading of the TMJ was analyzed both in male and female OI mice.

Materials And Methods: Forty-eight, 10-weeks-old male and female OI mice were divided into 3 groups: (1) Control group: unloaded group, (2) Saline + Loaded: Saline was injected for 2 weeks and then TMJ of mice was loaded for 5 days, (3) alendronate + loaded: alendronate was injected for 2 weeks and then TMJ of mice was loaded for 5 days. Mice in all the groups were euthanized 24-h after the final loading.

Results: Alendronate pretreatment led to significant increase in bone volume and tissue density. Histomorphometrically, alendronate treatment led to increase in mineralization, cartilage thickness and proteoglycan distribution. Increased mineralization paralleled decreased osteoclastic activity. Our immunohistochemistry revealed decreased expression of matrix metallopeptidase 13 and ADAM metallopeptidase with thrombospondin type 1 motif 5.

Conclusion: The findings of this research support that alendronate prevented the detrimental effects of loading on the extracellular matrix of the TMJ cartilage and subchondral bone.

References
1.
Van Beek E, Cohen L, Leroy I, Ebetino F, Lowik C, Papapoulos S . Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone. 2003; 33(5):805-11. DOI: 10.1016/j.bone.2003.07.007. View

2.
Fleisch H . Development of bisphosphonates. Breast Cancer Res. 2002; 4(1):30-4. PMC: 138713. DOI: 10.1186/bcr414. View

3.
Wang M, Sampson E, Jin H, Li J, Ke Q, Im H . MMP13 is a critical target gene during the progression of osteoarthritis. Arthritis Res Ther. 2013; 15(1):R5. PMC: 3672752. DOI: 10.1186/ar4133. View

4.
Blom A, van Lent P, Libregts S, Holthuysen A, van der Kraan P, van Rooijen N . Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum. 2006; 56(1):147-57. DOI: 10.1002/art.22337. View

5.
Palomo T, Vilaca T, Lazaretti-Castro M . Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. 2017; 24(6):381-388. DOI: 10.1097/MED.0000000000000367. View